- Home
- IMG vs UBX Comparison
IMG vs UBX Comparison
Compare IMG & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMG
- UBX
- Stock Information
- Founded
- IMG 2011
- UBX 2009
- Country
- IMG Hong Kong
- UBX United States
- Employees
- IMG N/A
- UBX N/A
- Industry
- IMG
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- IMG
- UBX Health Care
- Exchange
- IMG NYSE
- UBX Nasdaq
- Market Cap
- IMG 14.7M
- UBX 13.8M
- IPO Year
- IMG 2020
- UBX 2018
- Fundamental
- Price
- IMG $0.27
- UBX $0.29
- Analyst Decision
- IMG
- UBX Strong Buy
- Analyst Count
- IMG 0
- UBX 3
- Target Price
- IMG N/A
- UBX $4.67
- AVG Volume (30 Days)
- IMG 237.8K
- UBX 1.6M
- Earning Date
- IMG 08-18-2025
- UBX 08-05-2025
- Dividend Yield
- IMG N/A
- UBX N/A
- EPS Growth
- IMG N/A
- UBX N/A
- EPS
- IMG N/A
- UBX N/A
- Revenue
- IMG $3,785,663.00
- UBX N/A
- Revenue This Year
- IMG $99.05
- UBX N/A
- Revenue Next Year
- IMG $130.30
- UBX N/A
- P/E Ratio
- IMG N/A
- UBX N/A
- Revenue Growth
- IMG 109.62
- UBX N/A
- 52 Week Low
- IMG $0.25
- UBX $0.24
- 52 Week High
- IMG $8.00
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- IMG N/A
- UBX 20.80
- Support Level
- IMG N/A
- UBX $0.24
- Resistance Level
- IMG N/A
- UBX $0.83
- Average True Range (ATR)
- IMG 0.00
- UBX 0.09
- MACD
- IMG 0.00
- UBX -0.05
- Stochastic Oscillator
- IMG 0.00
- UBX 8.44
About IMG CIMG INC
CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.